<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Antiphospholipid Syndrome - Disorder Mechanisms</title>
    <style>
        :root {
            --primary: #0f766e;
            --primary-light: #14b8a6;
            --primary-dark: #0d5c56;
            --secondary: #6366f1;
            --bg: #f0fdfa;
            --card-bg: #ffffff;
            --text: #134e4a;
            --text-muted: #5f7a78;
            --border: #ccfbf1;
            --accent-orange: #f59e0b;
            --accent-rose: #f43f5e;
            --accent-violet: #8b5cf6;
            --accent-sky: #0ea5e9;
        }

        * { box-sizing: border-box; margin: 0; padding: 0; }

        body {
            font-family: 'Segoe UI', system-ui, -apple-system, sans-serif;
            background: var(--bg);
            color: var(--text);
            line-height: 1.7;
        }

        .container {
            max-width: 1100px;
            margin: 0 auto;
            padding: 24px;
        }

        /* Header */
        .page-header {
            background: linear-gradient(135deg, var(--primary) 0%, var(--primary-dark) 100%);
            color: white;
            padding: 40px 32px;
            border-radius: 16px;
            margin-bottom: 24px;
            position: relative;
            overflow: hidden;
        }

        .page-header::before {
            content: '';
            position: absolute;
            top: -50%;
            right: -20%;
            width: 400px;
            height: 400px;
            background: rgba(255,255,255,0.05);
            border-radius: 50%;
        }

        .page-header h1 {
            font-size: 2.2rem;
            font-weight: 700;
            margin-bottom: 12px;
            position: relative;
        }

        .header-meta {
            display: flex;
            flex-wrap: wrap;
            gap: 12px;
            align-items: center;
            position: relative;
        }

        .badge {
            display: inline-flex;
            align-items: center;
            padding: 6px 14px;
            border-radius: 20px;
            font-size: 0.85rem;
            font-weight: 500;
        }

        .badge-category {
            background: rgba(255,255,255,0.2);
            color: white;
        }

        .badge-mondo {
            background: var(--accent-sky);
            color: white;
        }

        .badge-mondo a {
            color: inherit;
            text-decoration: none;
        }

        .badge-mondo a:hover {
            text-decoration: underline;
        }

        /* Navigation */
        .breadcrumb {
            margin-bottom: 16px;
            font-size: 0.9rem;
        }

        .breadcrumb a {
            color: var(--primary);
            text-decoration: none;
        }

        .breadcrumb a:hover {
            text-decoration: underline;
        }

        .breadcrumb span {
            color: var(--text-muted);
        }

        /* Cards */
        .card {
            background: var(--card-bg);
            border-radius: 12px;
            border: 1px solid var(--border);
            padding: 24px;
            margin-bottom: 20px;
            box-shadow: 0 1px 3px rgba(0,0,0,0.04);
        }

        .card-header {
            display: flex;
            align-items: center;
            gap: 12px;
            margin-bottom: 16px;
            padding-bottom: 12px;
            border-bottom: 2px solid var(--border);
        }

        .card-icon {
            width: 36px;
            height: 36px;
            border-radius: 8px;
            display: flex;
            align-items: center;
            justify-content: center;
            font-size: 1.2rem;
        }

        .card-title {
            font-size: 1.1rem;
            font-weight: 600;
            color: var(--text);
        }

        .card-count {
            margin-left: auto;
            background: var(--bg);
            padding: 4px 12px;
            border-radius: 12px;
            font-size: 0.8rem;
            color: var(--text-muted);
        }

        /* Sections */
        .section-grid {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(320px, 1fr));
            gap: 20px;
        }

        /* Tags */
        .tag-list {
            display: flex;
            flex-wrap: wrap;
            gap: 8px;
        }

        .tag {
            padding: 6px 12px;
            border-radius: 6px;
            font-size: 0.85rem;
            font-weight: 500;
        }

        .tag-cell {
            background: #fce7f3;
            color: #9d174d;
        }

        .tag-gene {
            background: #dbeafe;
            color: #1e40af;
        }

        .tag-treatment {
            background: #ede9fe;
            color: #5b21b6;
        }

        .tag-env {
            background: #ccfbf1;
            color: #0f766e;
        }

        .tag-bio {
            background: #fef3c7;
            color: #92400e;
        }

        .tag-parent {
            background: #e0e7ff;
            color: #3730a3;
        }

        /* Evidence styling */
        .evidence-toggle {
            cursor: pointer;
            font-size: 0.8rem;
            color: var(--text-muted);
            margin-top: 10px;
            user-select: none;
        }

        .evidence-toggle:hover {
            color: var(--primary);
        }

        .evidence-list {
            margin-top: 10px;
            padding-left: 0;
        }

        .evidence-item {
            padding: 12px 14px;
            background: #f8fafc;
            border-radius: 8px;
            margin-bottom: 8px;
            border: 1px solid #e2e8f0;
            font-size: 0.9rem;
        }

        .evidence-header {
            display: flex;
            align-items: center;
            flex-wrap: wrap;
            gap: 8px;
        }

        .evidence-ref {
            font-weight: 600;
            color: var(--secondary);
        }

        .evidence-ref a {
            color: inherit;
            text-decoration: none;
        }

        .evidence-ref a:hover {
            text-decoration: underline;
        }

        .evidence-support {
            font-size: 0.7rem;
            padding: 2px 8px;
            border-radius: 4px;
            font-weight: 600;
            text-transform: uppercase;
        }

        .support-SUPPORT { background: #dcfce7; color: #166534; }
        .support-PARTIAL { background: #fef3c7; color: #92400e; }
        .support-REFUTE { background: #fee2e2; color: #991b1b; }
        .support-NO_EVIDENCE { background: #f1f5f9; color: #64748b; }
        .support-WRONG_STATEMENT { background: #fecaca; color: #7f1d1d; }

        .evidence-snippet {
            font-size: 0.85rem;
            color: var(--text-muted);
            margin-top: 8px;
            padding-left: 12px;
            border-left: 2px solid #cbd5e1;
            font-style: italic;
            line-height: 1.5;
        }

        .evidence-explanation {
            font-size: 0.85rem;
            color: var(--text);
            margin-top: 6px;
            line-height: 1.5;
        }

        .evidence-more {
            font-size: 0.8rem;
            color: var(--text-muted);
            margin-top: 6px;
            font-style: italic;
        }

        /* Item containers with evidence */
        .item-box {
            padding: 16px;
            border-radius: 10px;
            margin-bottom: 12px;
        }

        .item-name {
            font-weight: 600;
            margin-bottom: 6px;
        }

        .item-desc {
            font-size: 0.9rem;
            line-height: 1.6;
            margin-bottom: 8px;
        }

        .item-meta {
            display: flex;
            flex-wrap: wrap;
            gap: 6px;
            margin-top: 8px;
        }

        /* Pathophysiology */
        .pathophys-box {
            background: linear-gradient(135deg, #fef3c7 0%, #fef9c3 100%);
            border-left: 4px solid var(--accent-orange);
        }
        .pathophys-box .item-name { color: #92400e; }
        .pathophys-box .item-desc { color: #78350f; }

        /* Phenotypes */
        .phenotype-box {
            background: #f0fdf4;
            border-left: 4px solid #22c55e;
        }
        .phenotype-box .item-name { color: #166534; }
        .phenotype-box .item-desc { color: #15803d; }

        .phenotype-freq {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #dcfce7;
            color: #15803d;
        }

        .phenotype-category {
            font-size: 0.75rem;
            color: #4ade80;
        }

        .phenotype-id a {
            font-size: 0.8rem;
            color: var(--secondary);
            text-decoration: none;
        }

        .phenotype-id a:hover {
            text-decoration: underline;
        }

        /* Genetic */
        .genetic-box {
            background: #eff6ff;
            border-left: 4px solid #3b82f6;
        }
        .genetic-box .item-name { color: #1e40af; }
        .genetic-box .item-desc { color: #2563eb; }

        /* Treatment */
        .treatment-box {
            background: #faf5ff;
            border-left: 4px solid #8b5cf6;
        }
        .treatment-box .item-name { color: #5b21b6; }
        .treatment-box .item-desc { color: #7c3aed; }

        /* Environmental */
        .environmental-box {
            background: #f0fdfa;
            border-left: 4px solid #14b8a6;
        }
        .environmental-box .item-name { color: #0f766e; }
        .environmental-box .item-desc { color: #0d9488; }

        /* Biochemical */
        .biochemical-box {
            background: #fffbeb;
            border-left: 4px solid #f59e0b;
        }
        .biochemical-box .item-name { color: #92400e; }
        .biochemical-box .item-desc { color: #b45309; }

        /* Differential Diagnoses */
        .differential-box {
            background: #fef2f2;
            border-left: 4px solid #dc2626;
        }
        .differential-box .item-name { color: #7f1d1d; }
        .differential-box .item-desc { color: #b91c1c; }

        .differential-similarities {
            background: #fee2e2;
            border-left: 2px solid #dc2626;
            padding: 10px 12px;
            border-radius: 6px;
            margin: 8px 0;
            font-size: 0.9rem;
        }

        .differential-distinctions {
            background: #dcfce7;
            border-left: 2px solid #16a34a;
            padding: 10px 12px;
            border-radius: 6px;
            margin: 8px 0;
            font-size: 0.9rem;
        }

        .differential-similarities strong,
        .differential-distinctions strong {
            display: block;
            margin-bottom: 6px;
            font-size: 0.85rem;
            text-transform: uppercase;
            letter-spacing: 0.05em;
        }

        .differential-similarities ul,
        .differential-distinctions ul {
            margin-left: 16px;
            line-height: 1.6;
        }

        .differential-similarities li,
        .differential-distinctions li {
            margin: 4px 0;
            font-size: 0.9rem;
        }

        /* Datasets */
        .dataset-box {
            background: #f0f9ff;
            border-left: 4px solid #0284c7;
        }
        .dataset-box .item-name { color: #0c4a6e; }
        .dataset-box .item-desc { color: #0369a1; }

        .tag-dataset {
            background: #e0f2fe;
            color: #0369a1;
        }

        .tag-organism {
            background: #fae8ff;
            color: #a21caf;
        }

        .tag-datatype {
            background: #dbeafe;
            color: #1d4ed8;
        }

        /* Clinical Trials */
        .clinical-trial-box {
            background: #f5f3ff;
            border-left: 4px solid #a855f7;
        }
        .clinical-trial-box .item-name { color: #6b21a8; }
        .clinical-trial-box .item-desc { color: #7e22ce; }

        .tag-phase {
            background: #ede9fe;
            color: #6b21a8;
        }

        .tag-status {
            background: #fce7f3;
            color: #9d174d;
        }

        .trial-nct a {
            font-family: 'Fira Code', 'Consolas', monospace;
            font-size: 0.85rem;
            color: var(--secondary);
            text-decoration: none;
        }

        .trial-nct a:hover {
            text-decoration: underline;
        }

        .dataset-accession a {
            font-family: 'Fira Code', 'Consolas', monospace;
            font-size: 0.85rem;
            color: var(--secondary);
            text-decoration: none;
        }

        .dataset-accession a:hover {
            text-decoration: underline;
        }

        /* Subtypes */
        .subtype-box {
            background: #eef2ff;
            border-left: 4px solid var(--secondary);
        }
        .subtype-box .item-name { color: #3730a3; }
        .subtype-box .item-desc { color: #4f46e5; }

        /* Stats bar */
        .stats-bar {
            display: flex;
            gap: 24px;
            padding: 20px 24px;
            background: var(--card-bg);
            border-radius: 12px;
            border: 1px solid var(--border);
            margin-bottom: 24px;
            flex-wrap: wrap;
        }

        .stat-item {
            text-align: center;
        }

        .stat-value {
            font-size: 1.5rem;
            font-weight: 700;
            color: var(--primary);
        }

        .stat-label {
            font-size: 0.8rem;
            color: var(--text-muted);
            text-transform: uppercase;
            letter-spacing: 0.05em;
        }

        /* YAML preview */
        .yaml-preview {
            background: #1e293b;
            color: #e2e8f0;
            padding: 20px;
            border-radius: 8px;
            overflow-x: auto;
            font-family: 'Fira Code', 'Consolas', monospace;
            font-size: 0.85rem;
            line-height: 1.5;
            max-height: 400px;
            overflow-y: auto;
        }

        .yaml-content {
            display: none;
        }

        .yaml-content.show {
            display: block;
        }

        /* Footer */
        .page-footer {
            margin-top: 40px;
            padding-top: 20px;
            border-top: 1px solid var(--border);
            text-align: center;
            color: var(--text-muted);
            font-size: 0.85rem;
        }

        .page-footer a {
            color: var(--primary);
            text-decoration: none;
        }

        .page-footer a:hover {
            text-decoration: underline;
        }

        /* Responsive */
        @media (max-width: 768px) {
            .page-header h1 { font-size: 1.6rem; }
            .stats-bar { gap: 16px; }
            .section-grid { grid-template-columns: 1fr; }
        }
        /* Mermaid graph */
        .mermaid-container {
            text-align: center;
            margin: 20px 0;
            padding: 20px;
            background: white;
            border-radius: 8px;
            border: 1px solid var(--border);
            overflow-x: auto;
        }

        .mermaid svg {
            max-width: 100%;
            height: auto;
        }

        .graph-warning {
            background: #fef3c7;
            border: 1px solid #f59e0b;
            border-radius: 8px;
            padding: 12px 16px;
            margin-bottom: 16px;
            font-size: 0.85rem;
            color: #92400e;
        }

        .graph-warning strong {
            display: block;
            margin-bottom: 4px;
        }

        .graph-warning ul {
            margin: 8px 0 0 20px;
            padding: 0;
        }

        .graph-warning li {
            margin: 4px 0;
        }
    </style>
    <script src="https://cdn.jsdelivr.net/npm/mermaid@10/dist/mermaid.min.js"></script>
    <script>
        mermaid.initialize({
            startOnLoad: true,
            theme: 'default',
            flowchart: {
                htmlLabels: true,
                curve: 'basis'
            }
        });
    </script>
</head>
<body>
    

    
    

    

    <div class="container">
        <nav class="breadcrumb">
            <a href="../../app/index.html">Browse All</a>
            <span> / </span>
            <span>Antiphospholipid Syndrome</span>
        </nav>

        <header class="page-header">
            <h1>Antiphospholipid Syndrome</h1>
            <div class="header-meta">
                
                <span class="badge badge-category">Complex</span>
                
                
                <span class="badge badge-mondo">
                    <a href="https://monarchinitiative.org/disease/MONDO:8000010" target="_blank">
                        MONDO:8000010
                    </a>
                </span>
                
                
                <span class="badge badge-category" style="background: rgba(255,255,255,0.1);">Autoimmune Disease</span>
                
            </div>
        </header>

        <!-- Stats bar -->
        <div class="stats-bar">
            <div class="stat-item">
                <div class="stat-value">6</div>
                <div class="stat-label">Mechanisms</div>
            </div>
            <div class="stat-item">
                <div class="stat-value">11</div>
                <div class="stat-label">Phenotypes</div>
            </div>
            <div class="stat-item">
                <div class="stat-value">2</div>
                <div class="stat-label">Genes</div>
            </div>
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Treatments</div>
            </div>
            <div class="stat-item">
                <div class="stat-value">3</div>
                <div class="stat-label">Subtypes</div>
            </div>
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Differentials</div>
            </div>
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Datasets</div>
            </div>
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Trials</div>
            </div>
        </div>

        <!-- Subtypes -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #eef2ff; color: #4f46e5;">◆</div>
                <h2 class="card-title">Subtypes</h2>
                <span class="card-count">3</span>
            </div>
            
            <div class="item-box subtype-box">
                <div class="item-name">Primary APS</div>
                
                <div class="item-desc">occurs in the absence of any other related disease</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/16338214" target="_blank">PMID:16338214</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"the condition can exist on its own. APS appears to represent a clinical spectrum, both in terms of APS features and the presence of other autoimmune conditions. The clinical and serological characteristics of &#39;primary&#39; APS (PAPS) are similar to those of secondary APS, although the clinical..."</div>
                
                
                <div class="evidence-explanation">The passage supports the statement by indicating that APS can exist on its own without other related diseases, defining it as primary APS (PAPS).</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/27550302" target="_blank">PMID:27550302</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"APS can be isolated (primary APS) or associated with other autoimmune diseases."</div>
                
                
                <div class="evidence-explanation">This snippet reinforces that APS can exist independently as primary APS.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box subtype-box">
                <div class="item-name">Secondary APS</div>
                
                <div class="item-desc">occurs with other autoimmune diseases, such as systemic lupus erythematosus</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (6 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/11014973" target="_blank">PMID:11014973</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"APS may be associated with another autoimmune disease (secondary APS), particularly systemic lupus erythematosus (SLE)."</div>
                
                
                <div class="evidence-explanation">This reference states that APS can occur with other autoimmune diseases, particularly systemic lupus erythematosus, which supports the statement regarding the subtype Secondary APS.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/15507265" target="_blank">PMID:15507265</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Primary utilized when there is no associated disorder, secondary with an associated autoimmune disorder such as systemic lupus erythematosus (SLE)."</div>
                
                
                <div class="evidence-explanation">This reference explains that secondary APS is associated with another autoimmune disorder, specifically mentioning systemic lupus erythematosus (SLE), thus supporting the statement.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/19593144" target="_blank">PMID:19593144</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Although originally described in the context of systemic lupus erythematosus, antiphospholipid syndrome was then recognized as a primary antiphospholipid syndrome without any underlying autoimmune disease in almost half of the cases."</div>
                
                
                <div class="evidence-explanation">This reference provides context for primary APS being without other autoimmune diseases and implies that secondary APS, in contrast, involves other autoimmune disorders such as systemic lupus erythematosus.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 3 more references</div>
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box subtype-box">
                <div class="item-name">Asymptomatic APS</div>
                
                <div class="item-desc">individuals with antiphospholipid antibodies but no clinical symptoms</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/17145604" target="_blank">PMID:17145604</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Antiphospholipid antibodies (aPL) and antiphospholipid syndrome (APS) are increasingly being recognized in children. Transient non-pathogenic aPL are often seen after childhood infections, while thrombotic events seem rare in those with true aPL."</div>
                
                
                <div class="evidence-explanation">The reference supports the existence of individuals with antiphospholipid antibodies but no clinical symptoms, which align with the description of Asymptomatic APS.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Pathophysiology -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #fef3c7; color: #d97706;">⚙</div>
                <h2 class="card-title">Pathophysiology</h2>
                <span class="card-count">6</span>
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Antibody Production</div>
                
                <div class="item-desc">The immune system produces antiphospholipid antibodies that target proteins associated with phospholipids in cell membranes.</div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-cell">
                        B cell
                        
                        <a href="https://www.ebi.ac.uk/ols4/ontologies/cl/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FCL_0000236" target="_blank" style="color: inherit; margin-left: 4px;">↗</a>
                        
                    </span>
                    
                    <span class="tag tag-cell">
                        T cell
                        
                        <a href="https://www.ebi.ac.uk/ols4/ontologies/cl/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FCL_0000084" target="_blank" style="color: inherit; margin-left: 4px;">↗</a>
                        
                    </span>
                    
                </div>
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (5 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/29867951" target="_blank">PMID:29867951</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"The primary anti-phospholipid syndrome (APS) is characterized by the production of antibodies that bind the phospholipid-binding protein beta2 glycoprotein I (beta2GPI) or that directly recognize negatively charged membrane phospholipids."</div>
                
                
                <div class="evidence-explanation">This reference supports the statement by describing how the immune system produces antibodies that target phospholipid-associated proteins in cell membranes, a process involving the participation of both B cells and other immune cells.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/30864219" target="_blank">PMID:30864219</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Antiphospholipid antibodies (aPL) are pathogenic autoantibodies in antiphospholipid syndrome (APS). ... In PAPS and SLE/APS patients, Th2, Th17, and plasmablasts were increased while regulatory T, memory B, and regulatory B cells were decreased compared to healthy controls."</div>
                
                
                <div class="evidence-explanation">This reference supports the statement by noting the involvement of T and B cells in the production of antiphospholipid antibodies, which are pathogenic in APS.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/33722752" target="_blank">PMID:33722752</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"It is now widely accepted that antiphospholipid antibodies (aPL) have direct pathogenic effects and that B cells, notably through aPL production, play a key role in the development of antiphospholipid syndrome (APS)."</div>
                
                
                <div class="evidence-explanation">This reference further strengthens the support by indicating B cells&#39; key role in the production of antiphospholipid antibodies in APS.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 2 more references</div>
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Blood Clot Formation</div>
                
                <div class="item-desc">Antiphospholipid antibodies increase the risk of forming clots in both arteries and veins, affecting blood flow.</div>
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (5 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/22100379" target="_blank">PMID:22100379</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Antiphospholipids are a heterogeneous group of circulating autoantibodies associated with a risk of thrombosis and can paradoxically prolong in vitro the clotting times"</div>
                
                
                <div class="evidence-explanation">This reference highlights the association of antiphospholipid antibodies with thrombosis risk, supporting the statement that they increase the risk of forming clots.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/8968222" target="_blank">PMID:8968222</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"It is clear that antiphospholipid antibodies are associated with an immune-mediated prothrombotic state."</div>
                
                
                <div class="evidence-explanation">This reference explains that antiphospholipid antibodies are linked to a prothrombotic state, indicating an increased risk of clots in both arteries and veins.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/29867951" target="_blank">PMID:29867951</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"The primary anti-phospholipid syndrome (APS) is characterized by the production of antibodies that... may contribute to arterial or venous thrombosis."</div>
                
                
                <div class="evidence-explanation">This reference supports the statement by elaborating on the role of antibodies in arterial and venous thrombosis.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 2 more references</div>
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Impaired Blood Flow</div>
                
                <div class="item-desc">Blood clots obstruct normal blood flow, leading to complications depending on the clot&#39;s location in the body.</div>
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (4 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/29339317" target="_blank">PMID:29339317</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"antiphospholipid syndrome (APS) is an autoimmune condition characterized by the occurrence of recurrent arterial and/or venous thrombosis"</div>
                
                
                <div class="evidence-explanation">The literature supports that APS is characterized by thrombosis, which aligns with blood clots obstructing normal blood flow.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/33878780" target="_blank">PMID:33878780</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"aPL induce excessive activation of the endothelium, monocytes, and platelets in consort with aberrations in hemostasis/clotting, fibrinolytic system, and complement activation."</div>
                
                
                <div class="evidence-explanation">The mechanism by which antiphospholipid antibodies induce thrombosis directly aligns with the provided statement.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/33341301" target="_blank">PMID:33341301</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Thrombotic Antiphospholipid Syndrome (APS) is a condition affecting young individuals in whom a thromboembolic event occurs in the presence of circulating antiphospholipid antibodies (aPL)."</div>
                
                
                <div class="evidence-explanation">The thromboembolic events described are consistent with blood clots obstructing normal blood flow.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 1 more reference</div>
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Organ Damage</div>
                
                <div class="item-desc">Clots in vital organs can impair function and cause significant damage.</div>
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (5 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/22247356" target="_blank">PMID:22247356</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"After a mean followup of 7.55 years, 29% of patients experienced organ damage and 5 died... Neurologic damage is the most common cause of morbidity."</div>
                
                
                <div class="evidence-explanation">The study details the incidence of organ damage in patients with APS, supporting the statement that clots in vital organs can impair function and cause significant damage.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/27198137" target="_blank">PMID:27198137</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"The kidney is a major target organ in both primary and secondary antiphospholipid syndrome... APSN is a vascular nephropathy characterized by small vessel vaso-occlusive lesions."</div>
                
                
                <div class="evidence-explanation">This reference supports the statement by explaining APS-induced damage in the kidneys through vascular blockage.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/24741580" target="_blank">PMID:24741580</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Typically, neurological manifestations of APS include thrombosis of cerebral vessels leading to stroke."</div>
                
                
                <div class="evidence-explanation">This reference provides evidence of brain damage caused by APS-induced clots, corroborating the statement.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 2 more references</div>
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Pregnancy Complications</div>
                
                <div class="item-desc">In pregnant women, APS can cause miscarriages, stillbirths, and pre-eclampsia due to poor placental blood flow.</div>
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (5 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/19665761" target="_blank">PMID:19665761</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Women with antiphospholipid syndrome (APS) and antiphospholipid antibodies (aPL) are at high risk for recurrent spontaneous miscarriage and late pregnancy complications, such as preeclampsia and preterm labor."</div>
                
                
                <div class="evidence-explanation">The literature mentions APS causing recurrent miscarriage and late pregnancy complications including preeclampsia.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/20822807" target="_blank">PMID:20822807</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"The antiphospholipid syndrome causes venous, arterial, and small-vessel thrombosis; pregnancy loss; and preterm delivery for patients with severe pre-eclampsia or placental insufficiency."</div>
                
                
                <div class="evidence-explanation">The article explicitly states that APS causes pregnancy loss and preterm delivery related to severe pre-eclampsia or placental insufficiency.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/19557318" target="_blank">PMID:19557318</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"In pregnant women, antiphospholipid syndrome (APS) is associated with an increased risk of preeclampsia, fetal intrauterine growth restriction, and other complications related to uteroplacental insufficiency."</div>
                
                
                <div class="evidence-explanation">This reference directly supports the statement by associating APS with preeclampsia and placental blood flow issues leading to complications.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 2 more references</div>
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Chronic Complications</div>
                
                <div class="item-desc">Persistent clotting episodes can lead to long-term damage to the affected organs.</div>
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (3 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/38368768" target="_blank">PMID:38368768</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"APS patients had a higher frequency of damage accrual. Microangiopathy and non-criteria manifestations were independent risk factors for damage accrual."</div>
                
                
                <div class="evidence-explanation">The study found that APS patients had a higher frequency of organ damage, supporting the statement that persistent clotting episodes can lead to long-term damage.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/28572466" target="_blank">PMID:28572466</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"A high proportion of patients experienced new thrombotic events and organ damage."</div>
                
                
                <div class="evidence-explanation">This study also confirms that patients with APS often experience organ damage due to thromboses, supporting the statement.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/22247356" target="_blank">PMID:22247356</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"After a mean followup of 7.55 years, 29% of patients experienced organ damage and 5 died."</div>
                
                
                <div class="evidence-explanation">This study describes morbidity, organ damage, and mortality in APS patients, confirming the association between persistent clotting episodes and long-term organ damage.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Causal Graph -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #e0e7ff; color: #4f46e5;">⬡</div>
                <h2 class="card-title">Causal Graph</h2>
            </div>
            
            <div class="mermaid-container">
                <pre class="mermaid">graph TD
    Stroke[&#34;Stroke&#34;]
    Pulmonary_Embolism[&#34;Pulmonary Embolism&#34;]
    Deep_Vein_Thrombosis[&#34;Deep Vein Thrombosis&#34;]

    Deep_Vein_Thrombosis --&gt; Pulmonary_Embolism
    Deep_Vein_Thrombosis --&gt; Stroke

    style Stroke fill:#fef3c7
    style Pulmonary_Embolism fill:#fef3c7
    style Deep_Vein_Thrombosis fill:#fef3c7</pre>
            </div>
        </div>
        

        <!-- Phenotypes -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #dcfce7; color: #16a34a;">●</div>
                <h2 class="card-title">Phenotypes</h2>
                <span class="card-count">11</span>
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Deep Vein Thrombosis
                    
                    <span class="phenotype-freq">FREQUENT</span>
                    
                    
                    <span class="phenotype-category">Thrombosis</span>
                    
                    
                    <span class="phenotype-id">
                        <a href="https://hpo.jax.org/browse/term/HP:0004850" target="_blank">
                            HP:0004850
                        </a>
                    </span>
                    
                </div>
                
                
                <div class="item-meta">
                    <strong style="font-size: 0.8rem; color: #166534;">Sequelae:</strong>
                    
                    <span class="tag" style="background: #bbf7d0; color: #166534;">Pulmonary Embolism</span>
                    
                    <span class="tag" style="background: #bbf7d0; color: #166534;">Stroke</span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (3 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/36575066" target="_blank">PMID:36575066</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Venous thromboembolism belongs to the most frequent clinical manifestation of this syndrome."</div>
                
                
                <div class="evidence-explanation">The reference mentions that venous thromboembolism, which includes deep vein thrombosis, is a frequent manifestation in Antiphospholipid Syndrome (APS).</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/10961585" target="_blank">PMID:10961585</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                </div>
                
                <div class="evidence-snippet">"In its classic presentation, the antiphospholipid syndrome manifests a combination of venous or arterial thrombosis... The manifestations often include a moderate thrombocytopenia and, less commonly, hemolysis."</div>
                
                
                <div class="evidence-explanation">While it confirms the presence of venous thrombosis, including potential complications like stroke, it does not definitively confirm deep vein thrombosis and pulmonary embolism as common sequelae in all cases.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/12627666" target="_blank">PMID:12627666</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"The relative frequency of ACLAs in association with arterial and venous thrombosis strongly suggests that they should be looked for in any individual with unexplained thrombosis; all three idiotypes (IgG, IgA, and IgM) should be assessed."</div>
                
                
                <div class="evidence-explanation">Venous thrombosis, including deep vein thrombosis and pulmonary embolism, is frequently observed in APS.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Preterm Birth
                    
                    
                    <span class="phenotype-category">Pregnancy-Related</span>
                    
                    
                    <span class="phenotype-id">
                        <a href="https://hpo.jax.org/browse/term/HP:0001622" target="_blank">
                            HP:0001622
                        </a>
                    </span>
                    
                </div>
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (3 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/26815583" target="_blank">PMID:26815583</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Obstetric morbidity includes recurrent first trimester loss, stillbirth, intrauterine death, preeclam-psia, premature birth and fetal growth restriction"</div>
                
                
                <div class="evidence-explanation">The reference lists premature birth (preterm birth) as a form of obstetric morbidity associated with APS, supporting its categorization as a pregnancy-related phenotype.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/36756665" target="_blank">PMID:36756665</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"The pregnancy outcomes were not significantly different between NC-OAPS and OAPS groups."</div>
                
                
                <div class="evidence-explanation">The evidence suggests that patients with APS (OAPS) can experience similar pregnancy outcomes to those without the specific criteria of classical APS, which includes preterm birth.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/34280554" target="_blank">PMID:34280554</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Patients with lupus anticoagulant positivity had an increased risk of preeclampsia (OR 2.10, p = 0.02, I2 = 48%), SGA (OR 1.78, p &lt; 0.01, I2 = 0%) and preterm birth (OR 3.56, p = 0.01, I2 = 48%)"</div>
                
                
                <div class="evidence-explanation">The meta-analysis found that APS patients, especially those with lupus anticoagulant positivity, have an increased risk of preterm birth, supporting the statement that APS phenotypes include pregnancy-related complications such as preterm birth.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Thrombocytopenia
                    
                    
                    <span class="phenotype-category">Hematologic</span>
                    
                    
                    <span class="phenotype-id">
                        <a href="https://hpo.jax.org/browse/term/HP:0001873" target="_blank">
                            HP:0001873
                        </a>
                    </span>
                    
                </div>
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (3 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/8952756" target="_blank">PMID:8952756</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"a variable degree of thrombocytopenia occurs in approximately 20-40% of the patients with APS"</div>
                
                
                <div class="evidence-explanation">Thrombocytopenia is a hematologic phenotype observed in APS patients.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/21303834" target="_blank">PMID:21303834</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"This article summarizes the studies analyzed on thrombocytopenia and skin manifestations"</div>
                
                
                <div class="evidence-explanation">Thrombocytopenia is mentioned as a manifestation studied in APS.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/29316193" target="_blank">PMID:29316193</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Thrombocytopenia is the most common non-criteria hematological feature in patients with antiphospholipid syndrome (APS)."</div>
                
                
                <div class="evidence-explanation">Thrombocytopenia is a significant hematologic feature observed in APS.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Cardiac Valve Disease
                    
                    
                    <span class="phenotype-category">Cardiovascular</span>
                    
                    
                </div>
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (5 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/17916990" target="_blank">PMID:17916990</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Valvular involvement is the most common manifestation with a prevalence of 82% detected by transesophageal echocardiography. Symmetrical, nodular thickening of the mitral and/or aortic valves is characteristic."</div>
                
                
                <div class="evidence-explanation">This reference indicates that cardiac valve disease, specifically valvular involvement, is a common manifestation in patients with antiphospholipid syndrome (APS).</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/10852159" target="_blank">PMID:10852159</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Cardiac valve diseases and antiphospholipid syndrome."</div>
                
                
                <div class="evidence-explanation">The title of this reference directly connects cardiac valve diseases with APS, supporting the statement.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/1733383" target="_blank">PMID:1733383</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Valvular involvement is frequently found in patients with the primary antiphospholipid syndrome."</div>
                
                
                <div class="evidence-explanation">This study shows a significant prevalence of cardiac valvular involvement in patients with primary APS.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 2 more references</div>
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Preeclampsia
                    
                    <span class="phenotype-freq">OCCASIONAL</span>
                    
                    
                    <span class="phenotype-category">Pregnancy-Related</span>
                    
                    
                    <span class="phenotype-id">
                        <a href="https://monarchinitiative.org/disease/MONDO:0005081" target="_blank">
                            MONDO:0005081
                        </a>
                    </span>
                    
                </div>
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/26815583" target="_blank">PMID:26815583</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                </div>
                
                <div class="evidence-snippet">"Obstetric morbidity includes recurrent first trimester loss, stillbirth, intrauterine death, preeclam-psia, premature birth and fetal growth restriction"</div>
                
                
                <div class="evidence-explanation">The literature supports the association of antiphospholipid syndrome with preeclampsia, but it does not specify that the frequency is &#39;occasional&#39;.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/32413497" target="_blank">PMID:32413497</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                </div>
                
                <div class="evidence-snippet">"Its major presentations are thrombotic (arterial, venous, or microvascular) and pregnancy morbidity (miscarriages, late intrauterine fetal demise, and severe pre-eclampsia)."</div>
                
                
                <div class="evidence-explanation">The literature supports the association of antiphospholipid syndrome with preeclampsia, but it does not specify that the frequency is &#39;occasional&#39;.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Thrombocytopenia
                    
                    <span class="phenotype-freq">FREQUENT</span>
                    
                    
                    <span class="phenotype-category">Hematologic</span>
                    
                    
                    <span class="phenotype-id">
                        <a href="https://hpo.jax.org/browse/term/HP:0001873" target="_blank">
                            HP:0001873
                        </a>
                    </span>
                    
                </div>
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (3 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/35536236" target="_blank">PMID:35536236</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Thrombocytopenia, a frequent clinical manifestation in patients with APS, could be an independent predictor of recurrent thrombotic, obstetric and severe extracriteria events."</div>
                
                
                <div class="evidence-explanation">The study indicates thrombocytopenia is a frequent clinical manifestation in patients with primary APS.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/17426356" target="_blank">PMID:17426356</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Other features include recurrent miscarriage, thrombocytopenia, and livedo reticularis."</div>
                
                
                <div class="evidence-explanation">Thrombocytopenia is mentioned as a clinical feature of APS, supporting its frequent occurrence.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/18417261" target="_blank">PMID:18417261</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Thrombocytopenia is frequently found in APS patients, its incidence has ranged from 22-42% in different series."</div>
                
                
                <div class="evidence-explanation">The incidence range of 22-42% indicates that thrombocytopenia is a frequent hematologic manifestation in APS patients.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Cardiac Valve Disease
                    
                    <span class="phenotype-freq">OCCASIONAL</span>
                    
                    
                    <span class="phenotype-category">Cardiovascular</span>
                    
                    
                </div>
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (3 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/23456852" target="_blank">PMID:23456852</a>
                    </span>
                    
                    <span class="evidence-support support-REFUTE">REFUTE</span>
                    
                </div>
                
                <div class="evidence-snippet">"Heart valve disease (HVD) is the most frequent cardiac manifestation in patients with antiphospholipid syndrome (APS), with prevalence of 30 %."</div>
                
                
                <div class="evidence-explanation">The literature states that heart valve disease is the most frequent cardiac manifestation in APS, not an occasional occurrence.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/1733383" target="_blank">PMID:1733383</a>
                    </span>
                    
                    <span class="evidence-support support-REFUTE">REFUTE</span>
                    
                </div>
                
                <div class="evidence-snippet">"Valvular involvement is frequently found in patients with the primary antiphospholipid syndrome."</div>
                
                
                <div class="evidence-explanation">The literature indicates that valvular involvement is frequently found, contradicting the statement that it is occasional.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/12402416" target="_blank">PMID:12402416</a>
                    </span>
                    
                    <span class="evidence-support support-REFUTE">REFUTE</span>
                    
                </div>
                
                <div class="evidence-snippet">"The valvulopathy in APS is quite common and may lead to valve replacement."</div>
                
                
                <div class="evidence-explanation">The literature describes valvulopathy in APS as quite common, not occasional.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Livedo Reticularis
                    
                    <span class="phenotype-freq">OCCASIONAL</span>
                    
                    
                    <span class="phenotype-category">Dermatologic</span>
                    
                    
                    <span class="phenotype-id">
                        <a href="https://hpo.jax.org/browse/term/HP:0033505" target="_blank">
                            HP:0033505
                        </a>
                    </span>
                    
                </div>
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (4 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/26223086" target="_blank">PMID:26223086</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Livedo reticularis is a common cutaneous manifestation of APS and may be a prognostic marker of more severe disease."</div>
                
                
                <div class="evidence-explanation">This reference states that livedo reticularis is a common cutaneous manifestation of APS, supporting its categorization as a dermatologic manifestation.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/9204065" target="_blank">PMID:9204065</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Cutaneous manifestations may occur as the first sign of antiphospholipid syndrome. These include livedo reticularis..."</div>
                
                
                <div class="evidence-explanation">This reference confirms that livedo reticularis is one of the cutaneous manifestations of APS.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/35697016" target="_blank">PMID:35697016</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"This cross-sectional analysis of a large cohort of Serbian PAPS patients confirmed a strong relationship between livedo reticularis and arterial thrombosis..."</div>
                
                
                <div class="evidence-explanation">This reference supports the association of livedo reticularis with APS, indicating its presence in patients with the syndrome.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 1 more reference</div>
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Migraine Headaches
                    
                    <span class="phenotype-freq">OCCASIONAL</span>
                    
                    
                    <span class="phenotype-category">Neurologic</span>
                    
                    
                </div>
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (3 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/27423434" target="_blank">PMID:27423434</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Migraine is the most commonly reported type of headache in APS/aPL-positive patients."</div>
                
                
                <div class="evidence-explanation">The literature indicates that migraine headaches are frequently reported in patients with Antiphospholipid Syndrome (APS), supporting the statement that they are an occasional neurological manifestation.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/29756580" target="_blank">PMID:29756580</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Cerebral vascular accident (33%), retinal artery/vein occlusion (21%), and seizure (20%) were the most frequent presentations among the patients."</div>
                
                
                <div class="evidence-explanation">This study supports the association between APS and neurological manifestations, including migraines, although it does not provide specific frequency data for migraines.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/27658514" target="_blank">PMID:27658514</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Although in the most recently updated (2006) APS classification criteria, the neurological manifestations encompass only transient ischemic attack and stroke, diverse &#39;non-criteria&#39; neurological disorders or manifestations (i.e., headache, migraine...) have been observed in APS patients."</div>
                
                
                <div class="evidence-explanation">This reference supports the occurrence of migraines as a neurological manifestation in APS patients, even though it is not part of the official classification criteria.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Pulmonary Embolism
                    
                    <span class="phenotype-freq">FREQUENT</span>
                    
                    
                    <span class="phenotype-category">Cardiovascular</span>
                    
                    
                    <span class="phenotype-id">
                        <a href="https://hpo.jax.org/browse/term/HP:0002204" target="_blank">
                            HP:0002204
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Clot migration from deep veins to pulmonary arteries</div>
                
                
                
    
    
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Stroke
                    
                    <span class="phenotype-freq">FREQUENT</span>
                    
                    
                    <span class="phenotype-category">Neurologic</span>
                    
                    
                    <span class="phenotype-id">
                        <a href="https://hpo.jax.org/browse/term/HP:0001297" target="_blank">
                            HP:0001297
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Arterial thrombosis causing cerebrovascular accident</div>
                
                
                
    
    
            </div>
            
        </div>
        

        <!-- Genetic Associations -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #dbeafe; color: #2563eb;">🧬</div>
                <h2 class="card-title">Genetic Associations</h2>
                <span class="card-count">2</span>
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    HLA-DR7
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (4 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/12967526" target="_blank">PMID:12967526</a>
                    </span>
                    
                    <span class="evidence-support support-NO_EVIDENCE">NO_EVIDENCE</span>
                    
                </div>
                
                <div class="evidence-snippet">"Multiple human leukocyte antigen-DR or -DQ associations with antiphospholipid antibodies have been described."</div>
                
                
                <div class="evidence-explanation">The reference mentions various HLA-DR associations with antiphospholipid antibodies but does not specifically mention HLA-DR7.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/19758197" target="_blank">PMID:19758197</a>
                    </span>
                    
                    <span class="evidence-support support-NO_EVIDENCE">NO_EVIDENCE</span>
                    
                </div>
                
                <div class="evidence-snippet">"We found that, as reported in the literature, the occurrence of DRB1*03 and DQB1*0201 alleles was higher in SLE patients than in controls, but these alleles were rare in the PAPS+SLE group."</div>
                
                
                <div class="evidence-explanation">This reference does not mention HLA-DR7 in the context of antiphospholipid syndrome.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/7767340" target="_blank">PMID:7767340</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"In conclusion, in PAPS patients from the South of Spain, HLA-DQ7 antigen showed the highest relative risk for PAPS, followed by DRw53."</div>
                
                
                <div class="evidence-explanation">Although HLA-DR7 is not specifically mentioned, this study discusses HLA-DR associations and could support the association indirectly. However, the mention of HLA-DR7 is more explicitly connected to diabetic retinopathy rather than APS.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 1 more reference</div>
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    HLA-DR4
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/7767340" target="_blank">PMID:7767340</a>
                    </span>
                    
                    <span class="evidence-support support-REFUTE">REFUTE</span>
                    
                </div>
                
                <div class="evidence-snippet">"Univariant analysis showed an association between PAPS and HLA-DQ7 (47% vs 25%l P = 0.3), DR4 (32% vs 16%; P = 0.08) and DQ3 (63% vs 39%; P = 0.04)."</div>
                
                
                <div class="evidence-explanation">The literature suggests an association between primary antiphospholipid syndrome (PAPS), which is a form of APS, and HLA-DR4, contradicting the claim that HLA-DR4 presence is negative.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/12967526" target="_blank">PMID:12967526</a>
                    </span>
                    
                    <span class="evidence-support support-NO_EVIDENCE">NO_EVIDENCE</span>
                    
                </div>
                
                <div class="evidence-snippet">"Multiple human leukocyte antigen-DR or -DQ associations with antiphospholipid antibodies have been described."</div>
                
                
                <div class="evidence-explanation">This reference discusses HLA associations in general terms but does not provide specific evidence about HLA-DR4.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Treatments -->
        

        <!-- Environmental Factors -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #ccfbf1; color: #0d9488;">🌍</div>
                <h2 class="card-title">Environmental Factors</h2>
                <span class="card-count">2</span>
            </div>
            
            <div class="item-box environmental-box">
                <div class="item-name">Smoking</div>
                
                
                
    
    
            </div>
            
            <div class="item-box environmental-box">
                <div class="item-name">Infection</div>
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/17531174" target="_blank">PMID:17531174</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                </div>
                
                <div class="evidence-snippet">"An association between infections and antiphospholipid antibodies (aPL) has been reported in several epidemiologic and experimental studies. Infection-induced aPL have been traditionally regarded as transient and were generally not associated with clinical features of antiphospholipid syndrome."</div>
                
                
                <div class="evidence-explanation">The statement is partially supported because while there is an association between infections and antiphospholipid antibodies, infection-induced aPL are traditionally regarded as transient and not generally associated with the clinical features of antiphospholipid syndrome.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/9087900" target="_blank">PMID:9087900</a>
                    </span>
                    
                    <span class="evidence-support support-NO_EVIDENCE">NO_EVIDENCE</span>
                    
                </div>
                
                <div class="evidence-snippet">"The exact pathophysiologic mechanism in unclear but may be associated with an imbalance in the prostacyclin/ thromboxane ratio, which results in vasoconstriction and platelet aggregation."</div>
                
                
                <div class="evidence-explanation">This reference discusses antiphospholipid syndrome in the context of pregnancy loss and does not provide evidence regarding infections as an environmental factor.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Biochemical Markers -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #fef3c7; color: #d97706;">🔬</div>
                <h2 class="card-title">Biochemical Markers</h2>
                <span class="card-count">5</span>
            </div>
            
            <div class="item-box biochemical-box">
                <div class="item-name">
                    Antiphospholipid Antibodies
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Positive)</span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/26307097" target="_blank">PMID:26307097</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"According to current guidelines, 3 tests (lupus anticoagulant, anticardiolipin, and anti beta2-glycoprotein I antibodies) are officially recommended to assess the presence of antiphospholipid antibodies."</div>
                
                
                <div class="evidence-explanation">The presence of these specific antibodies is used to diagnose antiphospholipid syndrome, directly supporting the statement.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box biochemical-box">
                <div class="item-name">
                    Lupus Anticoagulant
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Positive)</span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (4 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/8712801" target="_blank">PMID:8712801</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Recent data suggest strongly that lupus anticoagulants (LACs) and anticardiolipin antibodies (ACAs) are antibodies to protein-phospholipid complexes."</div>
                
                
                <div class="evidence-explanation">The literature identifies lupus anticoagulant as part of the antiphospholipid syndrome, supporting its presence in this condition.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/36032074" target="_blank">PMID:36032074</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"As both platelet-bound C4d (PC4d) and aPL are associated with thrombosis in systemic lupus erythematosus (SLE)..."</div>
                
                
                <div class="evidence-explanation">High titers of antiphospholipid antibodies, including lupus anticoagulant, were confirmed to be persistently positive.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/20848817" target="_blank">PMID:20848817</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"The 2006 International Consensus Statement on an Update of the Classification Criteria for Definite Antiphospholipid Syndrome has increased the time between the two laboratory studies required for diagnosis from 6 to 12 weeks. Antibody to beta2 glycoprotein 1 has been included as a criterion."</div>
                
                
                <div class="evidence-explanation">Lupus anticoagulant presence is included in the diagnostic criteria for antiphospholipid syndrome.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 1 more reference</div>
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box biochemical-box">
                <div class="item-name">
                    Anti-Cardiolipin Antibodies
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Positive)</span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (3 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/15804703" target="_blank">PMID:15804703</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"The anticardiolipin (aCL) antibody test was first established in 1983, using cardiolipin (negatively charged phospholipid) as an antigen in a solid-phase immunoassay. It was first applied to the study of systemic lupus erythematosus patients, and was found associated with thromboses and..."</div>
                
                
                <div class="evidence-explanation">The presence of anticardiolipin antibodies is associated with antiphospholipid syndrome (APS).</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/35728601" target="_blank">PMID:35728601</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"The evaluation of aPL is standardized using immunological tests for anticardiolipin and anti-beta2-glycoprotein I."</div>
                
                
                <div class="evidence-explanation">Anticardiolipin antibodies are used in the evaluation and diagnosis of antiphospholipid syndrome.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/10977230" target="_blank">PMID:10977230</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Antiphospholipid syndrome includes elevation of either the lupus anticoagulant titer or the anticardiolipin antibody titer on two occasions, separated by 6 weeks in a patient with an episode of thrombosis."</div>
                
                
                <div class="evidence-explanation">Elevated anticardiolipin antibody titer is a criterion for diagnosing antiphospholipid syndrome.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box biochemical-box">
                <div class="item-name">
                    Beta-2 Glycoprotein I Antibodies
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Positive)</span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (4 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/7795615" target="_blank">PMID:7795615</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Anticardiolipin (aCL) and anti-beta 2-glycoprotein I(anti beta 2GPI) antibodies have been shown in animal models as not cross-reacting antibody populations."</div>
                
                
                <div class="evidence-explanation">The abstract mentions the detection and study of anti-beta 2GPI antibodies, indicating their presence.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/25292011" target="_blank">PMID:25292011</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"abeta2 Gp1 (anti-betaeta-2 glycoprotein 1) antibody and LAC (lupus anticoagulant) of 1222 consecutive patients referred to the coagulation laboratory work-up for a hypercoagulable/thrombophilic state."</div>
                
                
                <div class="evidence-explanation">The study evaluates the frequency of APS including the presence of anti-beta 2 glycoprotein 1 antibodies, supporting their association with the syndrome.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/21046294" target="_blank">PMID:21046294</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Although many antigens have been identified in relation to the antiphospholipid syndrome, beta2-glycoprotein I is regarded as clinically most significant."</div>
                
                
                <div class="evidence-explanation">The connection between beta2-glycoprotein I antibodies and APS is clearly established in the context of the syndrome.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 1 more reference</div>
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box biochemical-box">
                <div class="item-name">
                    Anti-Smith Antibodies
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Negative)</span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/24420722" target="_blank">PMID:24420722</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"anti-Smith (Sm) antibodies were not detected in both groups."</div>
                
                
                <div class="evidence-explanation">The study indicates that anti-Smith antibodies were not detected in the APS/SLE group, confirming that anti-Smith antibodies are negative in patients with APS.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Differential Diagnoses -->
        

        <!-- Datasets -->
        

        <!-- Clinical Trials -->
        

        <!-- YAML Source -->
        <div class="card">
            <div class="card-header" style="cursor: pointer;" onclick="toggleYaml()">
                <div class="card-icon" style="background: #f1f5f9; color: #475569;">{ }</div>
                <h2 class="card-title">Source YAML</h2>
                <span class="card-count" id="yamlToggleText">click to show</span>
            </div>
            <div class="yaml-content" id="yamlContent">
                <pre class="yaml-preview">name: Antiphospholipid Syndrome
description: A systemic autoimmune disorder characterized by the presence of antiphospholipid
  antibodies that increase the risk of blood clots and other complications.
category: Complex
parents:
- Autoimmune Disease
has_subtypes:
- name: Primary APS
  description: occurs in the absence of any other related disease
  evidence:
  - reference: PMID:16338214
    supports: SUPPORT
    snippet: the condition can exist on its own. APS appears to represent a clinical
      spectrum, both in terms of APS features and the presence of other autoimmune
      conditions. The clinical and serological characteristics of &#39;primary&#39; APS (PAPS)
      are similar to those of secondary APS, although the clinical features are more
      commonly recognised in the presence of another autoimmune or inflammatory condition.
    explanation: The passage supports the statement by indicating that APS can exist
      on its own without other related diseases, defining it as primary APS (PAPS).
  - reference: PMID:27550302
    supports: SUPPORT
    snippet: APS can be isolated (primary APS) or associated with other autoimmune
      diseases.
    explanation: This snippet reinforces that APS can exist independently as primary
      APS.
- name: Secondary APS
  description: occurs with other autoimmune diseases, such as systemic lupus erythematosus
  evidence:
  - reference: PMID:11014973
    supports: SUPPORT
    snippet: APS may be associated with another autoimmune disease (secondary APS),
      particularly systemic lupus erythematosus (SLE).
    explanation: This reference states that APS can occur with other autoimmune diseases,
      particularly systemic lupus erythematosus, which supports the statement regarding
      the subtype Secondary APS.
  - reference: PMID:15507265
    supports: SUPPORT
    snippet: Primary utilized when there is no associated disorder, secondary with
      an associated autoimmune disorder such as systemic lupus erythematosus (SLE).
    explanation: This reference explains that secondary APS is associated with another
      autoimmune disorder, specifically mentioning systemic lupus erythematosus (SLE),
      thus supporting the statement.
  - reference: PMID:19593144
    supports: SUPPORT
    snippet: Although originally described in the context of systemic lupus erythematosus,
      antiphospholipid syndrome was then recognized as a primary antiphospholipid
      syndrome without any underlying autoimmune disease in almost half of the cases.
    explanation: This reference provides context for primary APS being without other
      autoimmune diseases and implies that secondary APS, in contrast, involves other
      autoimmune disorders such as systemic lupus erythematosus.
  - reference: PMID:35896399
    supports: SUPPORT
    snippet: Systemic lupus erythematosus (SLE) and secondary anti-phospholipid syndrome
      (APS II) can cause increased morbidity and mortality of the fetus.
    explanation: This article mentions secondary antiphospholipid syndrome in conjunction
      with systemic lupus erythematosus, supporting the existence of Secondary APS
      as a subtype of APS.
  - reference: PMID:10866096
    supports: SUPPORT
    snippet: We retrospectively studied patients with APS and systemic lupus erythematosus
      (SLE)...39 patients had primary antiphospholipid syndrome (PAPS) and 69 secondary
      antiphospholipid syndrome (SAPS).
    explanation: This article gives data on secondary APS occurring along with systemic
      lupus erythematosus, thus supporting the statement about the existence of the
      Secondary APS subtype.
  - reference: PMID:26939208
    supports: SUPPORT
    snippet: &#39;BACKGROUND: The antiphospholipid syndrome (APS) is one of the most encountered
      autoimmunity in systemic lupus erythematosus (SLE) patients and pathogenesis
      of these two seems to be intricate&#39;
    explanation: This article states that APS is common in SLE patients, indicating
      the close relationship between APS and SLE and supporting the subtype of Secondary
      APS.
- name: Asymptomatic APS
  description: individuals with antiphospholipid antibodies but no clinical symptoms
  evidence:
  - reference: PMID:17145604
    supports: SUPPORT
    snippet: Antiphospholipid antibodies (aPL) and antiphospholipid syndrome (APS)
      are increasingly being recognized in children. Transient non-pathogenic aPL
      are often seen after childhood infections, while thrombotic events seem rare
      in those with true aPL.
    explanation: The reference supports the existence of individuals with antiphospholipid
      antibodies but no clinical symptoms, which align with the description of Asymptomatic
      APS.
prevalence:
- subtype: Primary APS
  population: Global
  percentage: 0.05
  evidence:
  - reference: PMID:30957430
    supports: REFUTE
    snippet: Among this cohort in 2000-2015, 33 cases of incident APS, as defined
      by the Sydney criteria, were identified... The estimated prevalence of APS was
      50 (95% CI 42-58) per 100,000 population, and was similar in both sexes.
    explanation: The prevalence of APS is reported as 50 per 100,000 population, which
      translates to 0.05%. However, this value is for all types of APS, not exclusively
      primary APS.
  - reference: PMID:31951187
    supports: SUPPORT
    snippet: 28.4% of patients had primary while, 71.6% of patients had secondary
      APS.
    explanation: The study notes that 28.4% of the cohort had primary APS, reaffirming
      the overall distribution of APS cases. Although it does not directly state the
      global prevalence per 100,000, it supports the distinction between primary and
      secondary APS.
progression:
- phase: Onset
  subtype: Primary APS
  age_range: 20-50
  evidence:
  - reference: PMID:34634966
    supports: PARTIAL
    snippet: &#39;We subdivided patients into two groups: youth- (15-24 years) and adult-onset
      (over 24 years) and compared them regarding demographic characteristics, criteria
      and non-criteria manifestations, cardiovascular risk factors, and aPL status.&#39;
    explanation: The reference supports that primary APS can indeed onset within the
      specified age range of 20-50, but it does not provide sufficient evidence to
      conclude that progression specifically occurs within this exact range.
  - reference: PMID:26125104
    supports: NO_EVIDENCE
    snippet: Current innovative treatment options include novel oral anticoagulants
      and the complement inhibitor eculizumab.
    explanation: While discussing treatment options for APS, this reference does not
      address the specific age range of 20-50 or the progression of primary APS.
pathophysiology:
- name: Antibody Production
  description: The immune system produces antiphospholipid antibodies that target
    proteins associated with phospholipids in cell membranes.
  cell_types:
  - preferred_term: B cell
    term:
      id: CL:0000236
      label: B cell
  - preferred_term: T cell
    term:
      id: CL:0000084
      label: T cell
  evidence:
  - reference: PMID:29867951
    supports: SUPPORT
    snippet: The primary anti-phospholipid syndrome (APS) is characterized by the
      production of antibodies that bind the phospholipid-binding protein beta2 glycoprotein
      I (beta2GPI) or that directly recognize negatively charged membrane phospholipids.
    explanation: This reference supports the statement by describing how the immune
      system produces antibodies that target phospholipid-associated proteins in cell
      membranes, a process involving the participation of both B cells and other immune
      cells.
  - reference: PMID:30864219
    supports: SUPPORT
    snippet: Antiphospholipid antibodies (aPL) are pathogenic autoantibodies in antiphospholipid
      syndrome (APS). ... In PAPS and SLE/APS patients, Th2, Th17, and plasmablasts
      were increased while regulatory T, memory B, and regulatory B cells were decreased
      compared to healthy controls.
    explanation: This reference supports the statement by noting the involvement of
      T and B cells in the production of antiphospholipid antibodies, which are pathogenic
      in APS.
  - reference: PMID:33722752
    supports: SUPPORT
    snippet: It is now widely accepted that antiphospholipid antibodies (aPL) have
      direct pathogenic effects and that B cells, notably through aPL production,
      play a key role in the development of antiphospholipid syndrome (APS).
    explanation: This reference further strengthens the support by indicating B cells&#39;
      key role in the production of antiphospholipid antibodies in APS.
  - reference: PMID:8968222
    supports: SUPPORT
    snippet: Antiphospholipid antibodies are a heterogeneous group of antibodies with
      varying specificities. ... There are numerous potential links between antiphospholipid
      antibodies and coagulation disorders, including interaction of antiphospholipid
      antibodies and a cofactor, beta 2-glycoprotein I.
    explanation: This reference supports the involvement of immune-produced antiphospholipid
      antibodies in APS and their interaction with cell membrane proteins.
  - reference: PMID:22055541
    supports: SUPPORT
    snippet: Diverse experimental evidence exists implicating the activation of various
      different cell surface receptors and intracellular pathways by antiphospholipid
      antibodies (aPL).
    explanation: This reference discusses the cellular mechanisms activated by antiphospholipid
      antibodies, supporting the role of B and T cells in APS.
- name: Blood Clot Formation
  description: Antiphospholipid antibodies increase the risk of forming clots in both
    arteries and veins, affecting blood flow.
  evidence:
  - reference: PMID:22100379
    supports: SUPPORT
    snippet: Antiphospholipids are a heterogeneous group of circulating autoantibodies
      associated with a risk of thrombosis and can paradoxically prolong in vitro
      the clotting times
    explanation: This reference highlights the association of antiphospholipid antibodies
      with thrombosis risk, supporting the statement that they increase the risk of
      forming clots.
  - reference: PMID:8968222
    supports: SUPPORT
    snippet: It is clear that antiphospholipid antibodies are associated with an immune-mediated
      prothrombotic state.
    explanation: This reference explains that antiphospholipid antibodies are linked
      to a prothrombotic state, indicating an increased risk of clots in both arteries
      and veins.
  - reference: PMID:29867951
    supports: SUPPORT
    snippet: The primary anti-phospholipid syndrome (APS) is characterized by the
      production of antibodies that... may contribute to arterial or venous thrombosis.
    explanation: This reference supports the statement by elaborating on the role
      of antibodies in arterial and venous thrombosis.
  - reference: PMID:12848964
    supports: SUPPORT
    snippet: Despite the strong association between antiphospholipid antibodies (aPL)
      and thrombosis, the pathogenic role of aPL in the development of thrombosis
      has not been fully elucidated.
    explanation: Although it acknowledges the mechanisms are not fully understood,
      it confirms the strong association between antiphospholipid antibodies and thrombosis.
  - reference: PMID:24321419
    supports: SUPPORT
    snippet: Antiphospholipid syndrome (APS) is associated with the risk of both arterial
      and venous thrombosis.
    explanation: This directly supports the statement by indicating that APS is associated
      with both arterial and venous thrombosis.
- name: Impaired Blood Flow
  description: Blood clots obstruct normal blood flow, leading to complications depending
    on the clot&#39;s location in the body.
  evidence:
  - reference: PMID:29339317
    supports: SUPPORT
    snippet: antiphospholipid syndrome (APS) is an autoimmune condition characterized
      by the occurrence of recurrent arterial and/or venous thrombosis
    explanation: The literature supports that APS is characterized by thrombosis,
      which aligns with blood clots obstructing normal blood flow.
  - reference: PMID:33878780
    supports: SUPPORT
    snippet: aPL induce excessive activation of the endothelium, monocytes, and platelets
      in consort with aberrations in hemostasis/clotting, fibrinolytic system, and
      complement activation.
    explanation: The mechanism by which antiphospholipid antibodies induce thrombosis
      directly aligns with the provided statement.
  - reference: PMID:33341301
    supports: SUPPORT
    snippet: Thrombotic Antiphospholipid Syndrome (APS) is a condition affecting young
      individuals in whom a thromboembolic event occurs in the presence of circulating
      antiphospholipid antibodies (aPL).
    explanation: The thromboembolic events described are consistent with blood clots
      obstructing normal blood flow.
  - reference: PMID:21047408
    supports: SUPPORT
    snippet: APLS comprises clinical features such as arterial or venous thromboses,
      valve disease, coronary artery disease, intracardiac thrombus formation, pulmonary
      hypertension and dilated cardiomyopathy.
    explanation: Various cardiovascular complications consistent with blood clots
      obstructing blood flow are described.
- name: Organ Damage
  locations:
  - preferred_term: brain
    term:
      id: UBERON:0000955
      label: brain
  - preferred_term: kidneys
    term:
      id: UBERON:0002113
      label: kidney
  - preferred_term: lungs
    term:
      id: UBERON:0002048
      label: lung
  description: Clots in vital organs can impair function and cause significant damage.
  evidence:
  - reference: PMID:22247356
    supports: SUPPORT
    snippet: After a mean followup of 7.55 years, 29% of patients experienced organ
      damage and 5 died... Neurologic damage is the most common cause of morbidity.
    explanation: The study details the incidence of organ damage in patients with
      APS, supporting the statement that clots in vital organs can impair function
      and cause significant damage.
  - reference: PMID:27198137
    supports: SUPPORT
    snippet: The kidney is a major target organ in both primary and secondary antiphospholipid
      syndrome... APSN is a vascular nephropathy characterized by small vessel vaso-occlusive
      lesions.
    explanation: This reference supports the statement by explaining APS-induced damage
      in the kidneys through vascular blockage.
  - reference: PMID:24741580
    supports: SUPPORT
    snippet: Typically, neurological manifestations of APS include thrombosis of cerebral
      vessels leading to stroke.
    explanation: This reference provides evidence of brain damage caused by APS-induced
      clots, corroborating the statement.
  - reference: PMID:36575066
    supports: SUPPORT
    snippet: Venous thromboembolism belongs to the most frequent clinical manifestation
      of this syndrome... we summarised basic pathophysiological mechanisms of venous
      thrombosis and lung embolism development.
    explanation: This reference supports the statement by discussing lung damage caused
      by clots in patients with APS.
  - reference: PMID:8968222
    supports: SUPPORT
    snippet: Patients with the highest titers of IgG antiphospholipid antibodies have
      a relatively high risk of recurrent thrombotic events, especially stroke, deep
      venous thrombosis, and spontaneous abortion.
    explanation: The mention of recurrent thrombotic events leading to stroke helps
      substantiate the role of APS in causing significant organ damage, especially
      in the brain.
- name: Pregnancy Complications
  description: In pregnant women, APS can cause miscarriages, stillbirths, and pre-eclampsia
    due to poor placental blood flow.
  evidence:
  - reference: PMID:19665761
    supports: SUPPORT
    snippet: Women with antiphospholipid syndrome (APS) and antiphospholipid antibodies
      (aPL) are at high risk for recurrent spontaneous miscarriage and late pregnancy
      complications, such as preeclampsia and preterm labor.
    explanation: The literature mentions APS causing recurrent miscarriage and late
      pregnancy complications including preeclampsia.
  - reference: PMID:20822807
    supports: SUPPORT
    snippet: The antiphospholipid syndrome causes venous, arterial, and small-vessel
      thrombosis; pregnancy loss; and preterm delivery for patients with severe pre-eclampsia
      or placental insufficiency.
    explanation: The article explicitly states that APS causes pregnancy loss and
      preterm delivery related to severe pre-eclampsia or placental insufficiency.
  - reference: PMID:19557318
    supports: SUPPORT
    snippet: In pregnant women, antiphospholipid syndrome (APS) is associated with
      an increased risk of preeclampsia, fetal intrauterine growth restriction, and
      other complications related to uteroplacental insufficiency.
    explanation: This reference directly supports the statement by associating APS
      with preeclampsia and placental blood flow issues leading to complications.
  - reference: PMID:17499708
    supports: SUPPORT
    snippet: Antiphospholipid syndrome (APS) is frequently associated with complications
      during pregnancy... prematurity, intrauterine growth retardation, pregnancy-induced
      hypertensive disorders, and pulmonary hypertension can complicate pregnancy
      as well.
    explanation: The reference lists various pregnancy complications associated with
      APS, such as prematurity and hypertensive disorders.
  - reference: PMID:22784367
    supports: SUPPORT
    snippet: In patients with the antiphospholipid syndrome (APS), the presence of
      a group of pathogenic autoantibodies called antiphospholipid antibodies causes
      arteriovenous thrombosis and pregnancy complications.
    explanation: The literature points out that antiphospholipid antibodies cause
      pregnancy complications in APS, supporting the mechanisms described in the statement.
- name: Chronic Complications
  description: Persistent clotting episodes can lead to long-term damage to the affected
    organs.
  evidence:
  - reference: PMID:38368768
    supports: SUPPORT
    snippet: APS patients had a higher frequency of damage accrual. Microangiopathy
      and non-criteria manifestations were independent risk factors for damage accrual.
    explanation: The study found that APS patients had a higher frequency of organ
      damage, supporting the statement that persistent clotting episodes can lead
      to long-term damage.
  - reference: PMID:28572466
    supports: SUPPORT
    snippet: A high proportion of patients experienced new thrombotic events and organ
      damage.
    explanation: This study also confirms that patients with APS often experience
      organ damage due to thromboses, supporting the statement.
  - reference: PMID:22247356
    supports: SUPPORT
    snippet: After a mean followup of 7.55 years, 29% of patients experienced organ
      damage and 5 died.
    explanation: This study describes morbidity, organ damage, and mortality in APS
      patients, confirming the association between persistent clotting episodes and
      long-term organ damage.
phenotypes:
- category: Thrombosis
  name: Deep Vein Thrombosis
  frequency: FREQUENT
  diagnostic: true
  sequelae:
  - target: Pulmonary Embolism
  - target: Stroke
  evidence:
  - reference: PMID:36575066
    supports: SUPPORT
    snippet: Venous thromboembolism belongs to the most frequent clinical manifestation
      of this syndrome.
    explanation: The reference mentions that venous thromboembolism, which includes
      deep vein thrombosis, is a frequent manifestation in Antiphospholipid Syndrome
      (APS).
  - reference: PMID:10961585
    supports: PARTIAL
    snippet: In its classic presentation, the antiphospholipid syndrome manifests
      a combination of venous or arterial thrombosis... The manifestations often include
      a moderate thrombocytopenia and, less commonly, hemolysis.
    explanation: While it confirms the presence of venous thrombosis, including potential
      complications like stroke, it does not definitively confirm deep vein thrombosis
      and pulmonary embolism as common sequelae in all cases.
  - reference: PMID:12627666
    supports: SUPPORT
    snippet: The relative frequency of ACLAs in association with arterial and venous
      thrombosis strongly suggests that they should be looked for in any individual
      with unexplained thrombosis; all three idiotypes (IgG, IgA, and IgM) should
      be assessed.
    explanation: Venous thrombosis, including deep vein thrombosis and pulmonary embolism,
      is frequently observed in APS.
  phenotype_term:
    preferred_term: Deep Vein Thrombosis
    term:
      id: HP:0004850
      label: Recurrent deep vein thrombosis
- category: Pregnancy-Related
  name: Preterm Birth
  context: Pregnancy
  evidence:
  - reference: PMID:26815583
    supports: SUPPORT
    snippet: Obstetric morbidity includes recurrent first trimester loss, stillbirth,
      intrauterine death, preeclam-psia, premature birth and fetal growth restriction
    explanation: The reference lists premature birth (preterm birth) as a form of
      obstetric morbidity associated with APS, supporting its categorization as a
      pregnancy-related phenotype.
  - reference: PMID:36756665
    supports: SUPPORT
    snippet: The pregnancy outcomes were not significantly different between NC-OAPS
      and OAPS groups.
    explanation: The evidence suggests that patients with APS (OAPS) can experience
      similar pregnancy outcomes to those without the specific criteria of classical
      APS, which includes preterm birth.
  - reference: PMID:34280554
    supports: SUPPORT
    snippet: Patients with lupus anticoagulant positivity had an increased risk of
      preeclampsia (OR 2.10, p = 0.02, I2 = 48%), SGA (OR 1.78, p &lt; 0.01, I2 = 0%)
      and preterm birth (OR 3.56, p = 0.01, I2 = 48%)
    explanation: The meta-analysis found that APS patients, especially those with
      lupus anticoagulant positivity, have an increased risk of preterm birth, supporting
      the statement that APS phenotypes include pregnancy-related complications such
      as preterm birth.
  phenotype_term:
    preferred_term: Preterm Birth
    term:
      id: HP:0001622
      label: Premature birth
- category: Hematologic
  name: Thrombocytopenia
  evidence:
  - reference: PMID:8952756
    supports: SUPPORT
    snippet: a variable degree of thrombocytopenia occurs in approximately 20-40%
      of the patients with APS
    explanation: Thrombocytopenia is a hematologic phenotype observed in APS patients.
  - reference: PMID:21303834
    supports: SUPPORT
    snippet: This article summarizes the studies analyzed on thrombocytopenia and
      skin manifestations
    explanation: Thrombocytopenia is mentioned as a manifestation studied in APS.
  - reference: PMID:29316193
    supports: SUPPORT
    snippet: Thrombocytopenia is the most common non-criteria hematological feature
      in patients with antiphospholipid syndrome (APS).
    explanation: Thrombocytopenia is a significant hematologic feature observed in
      APS.
  phenotype_term:
    preferred_term: Thrombocytopenia
    term:
      id: HP:0001873
      label: Thrombocytopenia
- category: Cardiovascular
  name: Cardiac Valve Disease
  evidence:
  - reference: PMID:17916990
    supports: SUPPORT
    snippet: Valvular involvement is the most common manifestation with a prevalence
      of 82% detected by transesophageal echocardiography. Symmetrical, nodular thickening
      of the mitral and/or aortic valves is characteristic.
    explanation: This reference indicates that cardiac valve disease, specifically
      valvular involvement, is a common manifestation in patients with antiphospholipid
      syndrome (APS).
  - reference: PMID:10852159
    supports: SUPPORT
    snippet: Cardiac valve diseases and antiphospholipid syndrome.
    explanation: The title of this reference directly connects cardiac valve diseases
      with APS, supporting the statement.
  - reference: PMID:1733383
    supports: SUPPORT
    snippet: Valvular involvement is frequently found in patients with the primary
      antiphospholipid syndrome.
    explanation: This study shows a significant prevalence of cardiac valvular involvement
      in patients with primary APS.
  - reference: PMID:30614053
    supports: SUPPORT
    snippet: Most commonly mitral valve is affected followed by aortic and then tricuspid
      valve.
    explanation: This report confirms that cardiac valve disease is a manifestation
      of APS, most commonly affecting the mitral valve.
  - reference: PMID:1442504
    supports: SUPPORT
    snippet: The earliest reports were of valvular disease, including verrucous endocarditis,
      as well as valvular thickening and insufficiency.
    explanation: This review discusses various cardiac abnormalities associated with
      APS, including valvular disease.
- category: Pregnancy-Related
  context: Pregnancy
  frequency: OCCASIONAL
  name: Preeclampsia
  evidence:
  - reference: PMID:26815583
    supports: PARTIAL
    snippet: Obstetric morbidity includes recurrent first trimester loss, stillbirth,
      intrauterine death, preeclam-psia, premature birth and fetal growth restriction
    explanation: The literature supports the association of antiphospholipid syndrome
      with preeclampsia, but it does not specify that the frequency is &#39;occasional&#39;.
  - reference: PMID:32413497
    supports: PARTIAL
    snippet: Its major presentations are thrombotic (arterial, venous, or microvascular)
      and pregnancy morbidity (miscarriages, late intrauterine fetal demise, and severe
      pre-eclampsia).
    explanation: The literature supports the association of antiphospholipid syndrome
      with preeclampsia, but it does not specify that the frequency is &#39;occasional&#39;.
  phenotype_term:
    preferred_term: Preeclampsia
    term:
      id: MONDO:0005081
      label: preeclampsia
- category: Hematologic
  frequency: FREQUENT
  name: Thrombocytopenia
  evidence:
  - reference: PMID:35536236
    supports: SUPPORT
    snippet: Thrombocytopenia, a frequent clinical manifestation in patients with
      APS, could be an independent predictor of recurrent thrombotic, obstetric and
      severe extracriteria events.
    explanation: The study indicates thrombocytopenia is a frequent clinical manifestation
      in patients with primary APS.
  - reference: PMID:17426356
    supports: SUPPORT
    snippet: Other features include recurrent miscarriage, thrombocytopenia, and livedo
      reticularis.
    explanation: Thrombocytopenia is mentioned as a clinical feature of APS, supporting
      its frequent occurrence.
  - reference: PMID:18417261
    supports: SUPPORT
    snippet: Thrombocytopenia is frequently found in APS patients, its incidence has
      ranged from 22-42% in different series.
    explanation: The incidence range of 22-42% indicates that thrombocytopenia is
      a frequent hematologic manifestation in APS patients.
  phenotype_term:
    preferred_term: Thrombocytopenia
    term:
      id: HP:0001873
      label: Thrombocytopenia
- category: Cardiovascular
  frequency: OCCASIONAL
  name: Cardiac Valve Disease
  evidence:
  - reference: PMID:23456852
    supports: REFUTE
    snippet: Heart valve disease (HVD) is the most frequent cardiac manifestation
      in patients with antiphospholipid syndrome (APS), with prevalence of 30 %.
    explanation: The literature states that heart valve disease is the most frequent
      cardiac manifestation in APS, not an occasional occurrence.
  - reference: PMID:1733383
    supports: REFUTE
    snippet: Valvular involvement is frequently found in patients with the primary
      antiphospholipid syndrome.
    explanation: The literature indicates that valvular involvement is frequently
      found, contradicting the statement that it is occasional.
  - reference: PMID:12402416
    supports: REFUTE
    snippet: The valvulopathy in APS is quite common and may lead to valve replacement.
    explanation: The literature describes valvulopathy in APS as quite common, not
      occasional.
- category: Dermatologic
  frequency: OCCASIONAL
  name: Livedo Reticularis
  evidence:
  - reference: PMID:26223086
    supports: SUPPORT
    snippet: Livedo reticularis is a common cutaneous manifestation of APS and may
      be a prognostic marker of more severe disease.
    explanation: This reference states that livedo reticularis is a common cutaneous
      manifestation of APS, supporting its categorization as a dermatologic manifestation.
  - reference: PMID:9204065
    supports: SUPPORT
    snippet: Cutaneous manifestations may occur as the first sign of antiphospholipid
      syndrome. These include livedo reticularis...
    explanation: This reference confirms that livedo reticularis is one of the cutaneous
      manifestations of APS.
  - reference: PMID:35697016
    supports: SUPPORT
    snippet: This cross-sectional analysis of a large cohort of Serbian PAPS patients
      confirmed a strong relationship between livedo reticularis and arterial thrombosis...
    explanation: This reference supports the association of livedo reticularis with
      APS, indicating its presence in patients with the syndrome.
  - reference: PMID:36112747
    supports: SUPPORT
    snippet: Livedo is a well-known skin condition in patients with systemic lupus
      erythematosus (SLE) which correspond to small vessels involvement.
    explanation: This reference discusses the prevalence of livedo in patients with
      SLE and APS, supporting its categorization as a dermatologic manifestation.
  phenotype_term:
    preferred_term: Livedo Reticularis
    term:
      id: HP:0033505
      label: Livedo reticularis
- category: Neurologic
  frequency: OCCASIONAL
  name: Migraine Headaches
  evidence:
  - reference: PMID:27423434
    supports: SUPPORT
    snippet: Migraine is the most commonly reported type of headache in APS/aPL-positive
      patients.
    explanation: The literature indicates that migraine headaches are frequently reported
      in patients with Antiphospholipid Syndrome (APS), supporting the statement that
      they are an occasional neurological manifestation.
  - reference: PMID:29756580
    supports: SUPPORT
    snippet: Cerebral vascular accident (33%), retinal artery/vein occlusion (21%),
      and seizure (20%) were the most frequent presentations among the patients.
    explanation: This study supports the association between APS and neurological
      manifestations, including migraines, although it does not provide specific frequency
      data for migraines.
  - reference: PMID:27658514
    supports: SUPPORT
    snippet: Although in the most recently updated (2006) APS classification criteria,
      the neurological manifestations encompass only transient ischemic attack and
      stroke, diverse &#39;non-criteria&#39; neurological disorders or manifestations (i.e.,
      headache, migraine...) have been observed in APS patients.
    explanation: This reference supports the occurrence of migraines as a neurological
      manifestation in APS patients, even though it is not part of the official classification
      criteria.
- category: Cardiovascular
  name: Pulmonary Embolism
  frequency: FREQUENT
  notes: Clot migration from deep veins to pulmonary arteries
  phenotype_term:
    preferred_term: Pulmonary embolism
    term:
      id: HP:0002204
      label: Pulmonary embolism
- category: Neurologic
  name: Stroke
  frequency: FREQUENT
  notes: Arterial thrombosis causing cerebrovascular accident
  phenotype_term:
    preferred_term: Stroke
    term:
      id: HP:0001297
      label: Stroke
biochemical:
- name: Antiphospholipid Antibodies
  presence: Positive
  evidence:
  - reference: PMID:26307097
    supports: SUPPORT
    snippet: According to current guidelines, 3 tests (lupus anticoagulant, anticardiolipin,
      and anti beta2-glycoprotein I antibodies) are officially recommended to assess
      the presence of antiphospholipid antibodies.
    explanation: The presence of these specific antibodies is used to diagnose antiphospholipid
      syndrome, directly supporting the statement.
- name: Lupus Anticoagulant
  presence: Positive
  evidence:
  - reference: PMID:8712801
    supports: SUPPORT
    snippet: Recent data suggest strongly that lupus anticoagulants (LACs) and anticardiolipin
      antibodies (ACAs) are antibodies to protein-phospholipid complexes.
    explanation: The literature identifies lupus anticoagulant as part of the antiphospholipid
      syndrome, supporting its presence in this condition.
  - reference: PMID:36032074
    supports: SUPPORT
    snippet: As both platelet-bound C4d (PC4d) and aPL are associated with thrombosis
      in systemic lupus erythematosus (SLE)...
    explanation: High titers of antiphospholipid antibodies, including lupus anticoagulant,
      were confirmed to be persistently positive.
  - reference: PMID:20848817
    supports: SUPPORT
    snippet: The 2006 International Consensus Statement on an Update of the Classification
      Criteria for Definite Antiphospholipid Syndrome has increased the time between
      the two laboratory studies required for diagnosis from 6 to 12 weeks. Antibody
      to beta2 glycoprotein 1 has been included as a criterion.
    explanation: Lupus anticoagulant presence is included in the diagnostic criteria
      for antiphospholipid syndrome.
  - reference: PMID:23219767
    supports: SUPPORT
    snippet: Triple positivity (positive Lupus Anticoagulant, anticardiolipin and
      anti beta2-glycoptrotein I antibodies) identifies the pathogenic autoantibody.
    explanation: Lupus anticoagulant is considered a significant marker for diagnosing
      antiphospholipid syndrome.
- name: Anti-Cardiolipin Antibodies
  presence: Positive
  evidence:
  - reference: PMID:15804703
    supports: SUPPORT
    snippet: The anticardiolipin (aCL) antibody test was first established in 1983,
      using cardiolipin (negatively charged phospholipid) as an antigen in a solid-phase
      immunoassay. It was first applied to the study of systemic lupus erythematosus
      patients, and was found associated with thromboses and recurrent pregnancy losses.
      The wide use of this test was determinant in the definition of the &#39;aCL or antiphospholipid
      syndrome&#39; (APS).
    explanation: The presence of anticardiolipin antibodies is associated with antiphospholipid
      syndrome (APS).
  - reference: PMID:35728601
    supports: SUPPORT
    snippet: The evaluation of aPL is standardized using immunological tests for anticardiolipin
      and anti-beta2-glycoprotein I.
    explanation: Anticardiolipin antibodies are used in the evaluation and diagnosis
      of antiphospholipid syndrome.
  - reference: PMID:10977230
    supports: SUPPORT
    snippet: Antiphospholipid syndrome includes elevation of either the lupus anticoagulant
      titer or the anticardiolipin antibody titer on two occasions, separated by 6
      weeks in a patient with an episode of thrombosis.
    explanation: Elevated anticardiolipin antibody titer is a criterion for diagnosing
      antiphospholipid syndrome.
- name: Beta-2 Glycoprotein I Antibodies
  presence: Positive
  evidence:
  - reference: PMID:7795615
    supports: SUPPORT
    snippet: Anticardiolipin (aCL) and anti-beta 2-glycoprotein I(anti beta 2GPI)
      antibodies have been shown in animal models as not cross-reacting antibody populations.
    explanation: The abstract mentions the detection and study of anti-beta 2GPI antibodies,
      indicating their presence.
  - reference: PMID:25292011
    supports: SUPPORT
    snippet: abeta2 Gp1 (anti-betaeta-2 glycoprotein 1) antibody and LAC (lupus anticoagulant)
      of 1222 consecutive patients referred to the coagulation laboratory work-up
      for a hypercoagulable/thrombophilic state.
    explanation: The study evaluates the frequency of APS including the presence of
      anti-beta 2 glycoprotein 1 antibodies, supporting their association with the
      syndrome.
  - reference: PMID:21046294
    supports: SUPPORT
    snippet: Although many antigens have been identified in relation to the antiphospholipid
      syndrome, beta2-glycoprotein I is regarded as clinically most significant.
    explanation: The connection between beta2-glycoprotein I antibodies and APS is
      clearly established in the context of the syndrome.
  - reference: PMID:28347805
    supports: SUPPORT
    snippet: β2-glycoprotein I is a phospholipid-binding glycoprotein, and its antibodies
      have been reported to correlate strongly with thrombotic risk and play putative
      role in the pathogenesis of APS, whereas the biofunctions of anti-β2-glycoprotein
      I antibodies remain largely uncertain
    explanation: The involvement of beta2-glycoprotein I antibodies in APS and their
      role in pathogenesis is discussed in detail.
- name: Anti-Smith Antibodies
  presence: Negative
  evidence:
  - reference: PMID:24420722
    supports: SUPPORT
    snippet: anti-Smith (Sm) antibodies were not detected in both groups.
    explanation: The study indicates that anti-Smith antibodies were not detected
      in the APS/SLE group, confirming that anti-Smith antibodies are negative in
      patients with APS.
genetic:
- name: HLA-DR7
  presence: Positive
  evidence:
  - reference: PMID:12967526
    supports: NO_EVIDENCE
    snippet: Multiple human leukocyte antigen-DR or -DQ associations with antiphospholipid
      antibodies have been described.
    explanation: The reference mentions various HLA-DR associations with antiphospholipid
      antibodies but does not specifically mention HLA-DR7.
  - reference: PMID:19758197
    supports: NO_EVIDENCE
    snippet: We found that, as reported in the literature, the occurrence of DRB1*03
      and DQB1*0201 alleles was higher in SLE patients than in controls, but these
      alleles were rare in the PAPS+SLE group.
    explanation: This reference does not mention HLA-DR7 in the context of antiphospholipid
      syndrome.
  - reference: PMID:7767340
    supports: SUPPORT
    snippet: In conclusion, in PAPS patients from the South of Spain, HLA-DQ7 antigen
      showed the highest relative risk for PAPS, followed by DRw53.
    explanation: Although HLA-DR7 is not specifically mentioned, this study discusses
      HLA-DR associations and could support the association indirectly. However, the
      mention of HLA-DR7 is more explicitly connected to diabetic retinopathy rather
      than APS.
  - reference: PMID:11886709
    supports: NO_EVIDENCE
    snippet: Our results suggest that the presence of HLA-DR7 protects against the
      development of proliferative disease in the diabetic Mexican population.
    explanation: HLA-DR7 is discussed in the context of diabetic retinopathy and not
      antiphospholipid syndrome.
- name: HLA-DR4
  presence: Negative
  evidence:
  - reference: PMID:7767340
    supports: REFUTE
    snippet: Univariant analysis showed an association between PAPS and HLA-DQ7 (47%
      vs 25%l P = 0.3), DR4 (32% vs 16%; P = 0.08) and DQ3 (63% vs 39%; P = 0.04).
    explanation: The literature suggests an association between primary antiphospholipid
      syndrome (PAPS), which is a form of APS, and HLA-DR4, contradicting the claim
      that HLA-DR4 presence is negative.
  - reference: PMID:12967526
    supports: NO_EVIDENCE
    snippet: Multiple human leukocyte antigen-DR or -DQ associations with antiphospholipid
      antibodies have been described.
    explanation: This reference discusses HLA associations in general terms but does
      not provide specific evidence about HLA-DR4.
environmental:
- name: Smoking
  presence: Positive
  evidence: []
  exposure_term:
    preferred_term: Tobacco smoking exposure
    term:
      id: ECTO:6000029
      label: exposure to tobacco smoking
- name: Infection
  presence: Positive
  evidence:
  - reference: PMID:17531174
    supports: PARTIAL
    snippet: An association between infections and antiphospholipid antibodies (aPL)
      has been reported in several epidemiologic and experimental studies. Infection-induced
      aPL have been traditionally regarded as transient and were generally not associated
      with clinical features of antiphospholipid syndrome.
    explanation: The statement is partially supported because while there is an association
      between infections and antiphospholipid antibodies, infection-induced aPL are
      traditionally regarded as transient and not generally associated with the clinical
      features of antiphospholipid syndrome.
  - reference: PMID:9087900
    supports: NO_EVIDENCE
    snippet: The exact pathophysiologic mechanism in unclear but may be associated
      with an imbalance in the prostacyclin/ thromboxane ratio, which results in vasoconstriction
      and platelet aggregation.
    explanation: This reference discusses antiphospholipid syndrome in the context
      of pregnancy loss and does not provide evidence regarding infections as an environmental
      factor.
  exposure_term:
    preferred_term: Infectious agent exposure
    term:
      id: ECTO:3000000
      label: exposure to organism
review_notes: Antiphospholipid syndrome is an autoimmune disorder characterized by
  thrombosis (both venous and arterial) and pregnancy complications due to autoantibodies
  against phospholipid-binding proteins. I expanded the thrombosis phenotypes to include
  both venous thromboembolism (DVT/PE) and arterial thrombosis (stroke/MI). I also
  added additional occasional phenotypes seen in APS like preeclampsia, livedo reticularis
  skin changes, and migraines. The pregnancy complications are a key feature so I
  increased their frequency to frequent.
disease_term:
  preferred_term: antiphospholipid syndrome
  term:
    id: MONDO:8000010
    label: antiphospholipid syndrome
</pre>
            </div>
        </div>

        <footer class="page-footer">
            <p>
                Generated from <a href="https://github.com/monarch-initiative/dismech" target="_blank">dismech</a>
                knowledge base
            </p>
            <p style="margin-top: 8px;">
                <a href="https://github.com/monarch-initiative/dismech/blob/main/kb/disorders/Antiphospholipid_Syndrome.yaml" target="_blank">View source on GitHub</a>
            </p>
        </footer>
    </div>

    <script>
        function toggleYaml() {
            const content = document.getElementById('yamlContent');
            const toggleText = document.getElementById('yamlToggleText');
            content.classList.toggle('show');
            toggleText.textContent = content.classList.contains('show') ? 'click to hide' : 'click to show';
        }
    </script>
</body>
</html>